Valuation: LivaNova PLC

Capitalization 3.94B 3.36B 3.08B 2.92B 5.41B 377B 5.46B 36.72B 14.3B 179B 14.79B 14.48B 622B P/E ratio 2026 *
27.2x
P/E ratio 2027 * 22.3x
Enterprise value 3.65B 3.11B 2.85B 2.7B 5.01B 349B 5.05B 33.98B 13.23B 166B 13.69B 13.4B 575B EV / Sales 2026 *
2.42x
EV / Sales 2027 * 2.34x
Free-Float
98.49%
Yield 2026 *
-
Yield 2027 * -
1 day+2.37%
1 week+24.59%
Current month+19.38%
1 month+14.29%
3 months+12.27%
6 months+26.72%
Current year+16.61%
1 week 66.8
Extreme 66.8
72.78
1 month 56.44
Extreme 56.44
72.78
Current year 56.44
Extreme 56.44
72.78
1 year 41.02
Extreme 41.015
72.78
3 years 32.48
Extreme 32.48
72.78
5 years 32.48
Extreme 32.48
93.89
10 years 32.48
Extreme 32.48
131.54
Manager TitleAgeSince
Chief Executive Officer 53 29/02/2024
Director of Finance/CFO 56 30/10/2020
Investor Relations Contact - 31/07/2022
Director TitleAgeSince
Director/Board Member 68 18/10/2015
Director/Board Member 58 18/10/2015
Chairman 74 08/06/2021
Change 5d. change 1-year change 3-years change Capi.($)
+2.37%+24.59%+58.63%+52.46% 3.94B
+2.17%-3.24%-36.09%-23.66% 147B
+3.06%-1.25%-10.48%-13.57% 98.63B
+1.45%+0.62%+51.88%+79.74% 57.86B
+0.47%-14.70%-6.27%+52.60% 50.77B
+3.05%+2.32%-15.87%-41.58% 40.64B
-1.78%-14.94% - - 32.6B
+3.05%+2.79%-28.11%-49.76% 23.59B
-3.17%+0.68%+42.20%-13.32% 22.05B
+4.46%-1.00%-9.55%0.00% 20.68B
Average +1.41%-0.39%+5.15%+4.77% 49.77B
Weighted average by Cap. +1.49%-3.27%-8.59%-1.03%

Financials

2026 *2027 *
Net sales 1.51B 1.29B 1.18B 1.12B 2.07B 144B 2.09B 14.05B 5.47B 68.46B 5.66B 5.54B 238B 1.61B 1.38B 1.26B 1.19B 2.21B 154B 2.24B 15.04B 5.86B 73.27B 6.06B 5.93B 255B
Net income 146M 125M 114M 108M 201M 14B 203M 1.36B 531M 6.64B 549M 537M 23.07B 179M 153M 140M 132M 246M 17.13B 248M 1.67B 649M 8.12B 671M 657M 28.22B
Net Debt -294M -251M -230M -218M -403M -28.14B -407M -2.74B -1.07B -13.35B -1.1B -1.08B -46.38B -167M -143M -131M -124M -229M -16B -232M -1.56B -606M -7.59B -627M -614M -26.36B
Logo LivaNova PLC
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
Employees
3,300
Date Price Change Volume
12/05/26 71.75 $ +2.37% 1,019,301
11/05/26 70.09 $ -2.46% 1,085,060
08/05/26 71.86 $ +1.32% 921,188
07/05/26 70.92 $ +7.04% 1,788,793
06/05/26 66.26 $ +15.05% 1,932,806
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
71.75USD
Average target price
80.18USD
Spread / Average Target
+11.75%

Quarterly revenue - Rate of surprise